- Home
- TDS vs DNTH Comparison
TDS vs DNTH Comparison
Compare TDS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDS | DNTH |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | 4000 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TDS | DNTH |
|---|---|---|
| Price | $41.37 | $86.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $53.33 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 748.9K | 404.8K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $1.72 | $29.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.60 | $16.77 |
| 52 Week High | $49.12 | $96.50 |
Technical Indicators
Market Signals| Indicator | TDS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 46.99 |
| Support Level | $37.18 | $82.00 |
| Resistance Level | $44.30 | $90.23 |
| Average True Range (ATR) | 1.52 | 4.60 |
| MACD | -0.46 | -0.84 |
| Stochastic Oscillator | 2.78 | 35.95 |
Price Performance
Historical ComparisonAbout TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides communications services to customers through broadband, video, voice, and wireless connections. The company has two reportable segments: TDS Telecom and Array. The majority of its revenue is generated from the TDS Telecom segment, which generates revenue by providing broadband, video, voice, and wireless services. The Array segment generates its revenue mainly by leasing tower space on Array-owned towers to customers.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.